{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:57:02Z","timestamp":1777395422006,"version":"3.51.4"},"reference-count":33,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2018,2,6]]},"abstract":"<jats:p>\n                    Analysis of cerebrospinal fluid (CSF) is one of the key tools for the state-of-the-art differential diagnosis of dementias. Dementia due to Alzheimer\u2019s disease (AD) is characterized by elevated CSF levels of total Tau (tTau) and phospho-181-Tau (pTau) and low CSF amyloid-\u03b2\n                    <jats:sub>42<\/jats:sub>\n                    (A\u03b2\n                    <jats:sub>42<\/jats:sub>\n                    ). Discrepancies in the laboratory analysis of human materials are well known and much effort has been put into harmonization procedures. In this study, we measured CSF biomarkers of more than 100 patients obtained under clinical routine conditions in two different clinical laboratories. The CSF biomarker levels obtained from the two different sites were significantly correlated: R\n                    <jats:sup>2<\/jats:sup>\n                    \u200a=\u200a0.7129 (tTau, p\u200a&lt;\u200a0.001), 0.7914 (pTau, p\u200a&lt;\u200a0.001), 0.5078 (A\u03b2\n                    <jats:sub>42<\/jats:sub>\n                    , p\u200a&lt;\u200a0.001), 0.5739 (A\u03b2\n                    <jats:sub>40<\/jats:sub>\n                    , p\u200a&lt;\u200a0.001), and 0.4308 (A\u03b2\n                    <jats:sub>42\/40<\/jats:sub>\n                    , p\u200a&lt;\u200a0.001). However, the diagnostic classifications of the A\u03b2\n                    <jats:sub>42<\/jats:sub>\n                    , tTau, and pTau levels of identical subjects into normal versus pathological range made by the two different sites showed substantial discrepancies (31.5%, 29.6%, and 25.0% discordant cases, respectively). Applying A\u03b2\n                    <jats:sub>42\/40<\/jats:sub>\n                    , instead of CSF A\u03b2\n                    <jats:sub>42<\/jats:sub>\n                    alone, lead to a reduction of the discordant cases to 16.8%. Our findings suggest that CSF A\u03b2\n                    <jats:sub>42\/40<\/jats:sub>\n                    can outperform A\u03b2\n                    <jats:sub>42<\/jats:sub>\n                    as a biomarker for AD neuropathology, not only under well-controlled study conditions but also in real life clinical routine. Thus, we recommend the inclusion of A\u03b2\n                    <jats:sub>42\/40<\/jats:sub>\n                    as a CSF biomarker in the diagnostic procedure.\n                  <\/jats:p>","DOI":"10.3233\/jad-170793","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T13:01:30Z","timestamp":1517922090000},"page":"203-212","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Reproducibility of Alzheimer\u2019s Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions"],"prefix":"10.1177","volume":"62","author":[{"given":"Jonathan","family":"Vogelgsang","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Georg-August-University, Goettingen, Germany"}]},{"given":"Dirk","family":"Wedekind","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Georg-August-University, Goettingen, Germany"}]},{"given":"Caroline","family":"Bouter","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Medical Center Goettingen (UMG), Georg-August-University, Goettingen, Germany"}]},{"given":"Hans-W.","family":"Klafki","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Georg-August-University, Goettingen, Germany"}]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Georg-August-University, Goettingen, Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany"},{"name":"Department of Medical Science, iBiMED, University of Aveiro, Portugal"}]}],"member":"179","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2013.01.001"},{"key":"ref002","unstructured":"DeuschlG, MaierW (2016) S3-Leitlinie Demenzen. Deutsche Gesellschaft f\u00fcr Neurologie, Hrsg. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie, S3-Leitlinie \u201cDemenzen\u201d, http:\/\/www.dgn.org\/leitlinien, posted 25 January 2016, Accessed 29 November, 2017."},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.02.004"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.00818.x"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160398"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(03)00086-1"},{"key":"ref008","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-015-0114-5"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-140771"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160722"},{"key":"ref011","first-page":"2094","volume":"289","author":"Sunderland T","year":"2003","journal-title":"Psychiatry Interpers Biol Process"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.167791"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00070-3"},{"key":"ref014","first-page":"1","volume":"6","author":"Ritchie C","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30238-1"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2006.07.009"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2009.008232"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2016.05.014"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1159\/000100926"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.274"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu367"},{"key":"ref023","unstructured":"The Alzheimer\u2019s Association QC program for CSF biomarkers, http:\/\/www.neurochem.gu.se\/TheAlzAssQCprogram, Last updated 17 November 2017, Accessed 29 November 2017."},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2016.02.034"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2015-0733"},{"key":"ref026","first-page":"1","volume":"11","author":"Blennow K","year":"2014","journal-title":"Alzheimers Dement"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0225-7"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.01.010"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.09.009"},{"key":"ref030","unstructured":"IBL International (2015) Tau total ELISA, http:\/\/www.iblinternational.com\/media\/catalog\/product\/r\/e\/re59631_ifu_en_tau_total_elisa_2015-12_1.pdf, Accessed 29 November 2017."},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.02.003"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70178-3"},{"key":"ref033","doi-asserted-by":"publisher","DOI":"10.1602\/neurorx.1.2.213"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-170793","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-170793","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-170793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:05:44Z","timestamp":1777370744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-170793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2,6]]}},"alternative-id":["10.3233\/JAD-170793"],"URL":"https:\/\/doi.org\/10.3233\/jad-170793","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]}}}